Serina Therapeutics, Inc. (SER) - מזומן למניה

Serina Pharma - לוגו גרפי של המנפיק SER

Serina Therapeutics, Inc. (SER) is developing a polymer drug delivery system for the treatment of neurological pathologies. The current cash per share, with GURU.Markets data illustrated on this chart, equals 0.72. This is supported by the implementation of POZ technology for rare injections and the availability of a proprietary, patent-protected POZ-GK platform, although final profit depends on clinical trial results.

Serina (SER) - מזומנים למניה מ-28.03.2024 עד 21.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור serinatherapeutics.com (SER)

- שווי שוק ותחזית יעד של אנליסטים:
- מדדי זמינות כספים ותזרימי מזומנים:
ניתוח כללי של החברה:Serina Therapeutics, Inc. - SER
דוגמת מוצר של Serina Therapeutics, Inc.

For Serina Therapeutics, Inc. (SER), which develops costly polymer drug delivery technologies, liquidity is critical for sustaining preclinical research. This metric is calculated by dividing total cash reserves by the number of shares outstanding. Analyzing cash per share allows for an assessment of the real value of the liquid collateral backing each security. This determines the company's resilience to market shocks. A high cash level guarantees the issuer's survival during the prolonged development of therapies.